Dec 09, 2024
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Dec 03, 2024
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Dec 02, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 25, 2024
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Nov 20, 2024
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Nov 05, 2024
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Oct 31, 2024
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
Oct 31, 2024
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Oct 30, 2024
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
Oct 01, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 03, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 03, 2024
Karyopharm to Participate at Upcoming Investor Conferences
Aug 06, 2024
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Jul 31, 2024
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
Jul 01, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 01, 2024
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
May 29, 2024
Karyopharm to Participate at the Jefferies Global Healthcare Conference
May 02, 2024
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Apr 24, 2024
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Apr 01, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)